Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARP: Varenicline for Alcohol Use Disorder in HIV Patients
NCT06006143Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of varenicline in alcohol use disorder (AUD), sponsored by Yale University. Primary endpoints: Proportion of participants who complete enrollment and duration of sessions at 12 weeks, Number of sessions completed at 12 weeks and 2 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
varenicline
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06006143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006143.